Mounjaro Dominates India Weight-Loss; Wegovy Surges 70% After Price Cuts

• Eli Lilly's Mounjaro leads India's weight-loss market with an 86% share, achieving Rs 108 crore sales in November.
• Novo Nordisk's Wegovy is challenging Mounjaro after 30-35% price cuts, boosting its market share from 9% to 14% in November.
• Wegovy's price reduction led to a 70% consumption jump in 15 days, with November sales reaching Rs 27 crore.
• The GLP-1 agonist segment for weight management has grown tenfold in five years to Rs 1,047 crore, driven by urban India.
• Maharashtra accounts for 24% of GLP-1 sales, while Delhi-NCR and northern states contribute 16%, indicating regional disparities in adoption.

Why It Matters: Drug price wars are making weight-loss treatments more accessible in India.